Tempus AI rises after Q1 results, annual rev outlook surpass estimates

Shares of Tempus AI TEM.O up 5.1% at $54.83 on Weds after genetics testing firm's qtrly report and rev outlook please

Chicago, Illinois-based co, which is backed by Japan's SoftBank 9984.T, late Tues said Q1 rev grew 75% y/y to $255.7 mln, topping Wall Street analysts' estimate of $248.1 mln

Adj loss/sh in qtr of 24 cents was below 27 cents/sh loss expected

Co boosted its 2025 rev guidance slightly to $1.25 bln, from prior outlook of $1.24 bln, vs consensus view of $1.22 bln

“Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos. We believe this is just the beginning as more and more healthcare providers and life science companies embrace AI," founder and CEO Eric Lefkofsky said in the statement

TEM's shares on Apr 23 jumped ~15% to $49.55 after co unveiled multi-year collaborations with British drugmaker AstraZeneca AZN.L and Pathos AI, which include $200 mln in data licensing and model development fees to Tempus

With advance on Weds, TEM shares up ~63% YTD

Half of 12 analysts covering TEM rate stock "strong buy" or "buy", rest "hold" and the median PT is $65, latest LSEG data shows